Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019

Author:

Knopman David S.1,Jones David T.12,Greicius Michael D.3

Affiliation:

1. Department of Neurology, Mayo Clinic Rochester Minnesota USA

2. Department of Radiology Mayo Clinic Rochester Minnesota USA

3. Department of Neurology and Neurological Sciences Stanford University School of Medicine Stanford California USA

Funder

National Science Foundation

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

Reference12 articles.

1. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

2. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

3. EMERGE and EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer's Disease (https://investors.biogen.com/static-files/ddd45672-9c7e-4c99-8a06-3b557697c06f).2019.

4. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

5. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Cited by 377 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3